Tumour tissue transport after intraperitoneal anticancer drug delivery

被引：27
作者：
Carlier, Charlotte [1 ]
Mathys, Ada [1 ]
De Jaeghere, Emiel [2 ]
Steuperaert, Margo [3 ]
De Wever, Olivier [2 ,4 ]
Ceelen, Wim [1 ,4 ]
机构：
[1] Univ Ghent, Dept Surg, Expt Surg Lab, Ghent, Belgium
[2] Univ Ghent, Dept Radiat Oncol & Expt Canc Res, Ghent, Belgium
[3] Univ Ghent, Biofluid Tissue & Solid Mech Med Applicat bioMMed, Dept Elect & Informat Syst, iMinds Med IT Dept, Ghent, Belgium
[4] Univ Ghent, CRIG, Ghent, Belgium
来源：
INTERNATIONAL JOURNAL OF HYPERTHERMIA | 2017年 / 33卷 / 05期
关键词：
Intraperitoneal; carcinomatosis; drug delivery; pharmacokinetics; INTERSTITIAL FLUID PRESSURE; INTENSITY FOCUSED ULTRASOUND; AEROSOL CHEMOTHERAPY PIPAC; PANCREATIC DUCTAL ADENOCARCINOMA; HUMAN OSTEOSARCOMA XENOGRAFTS; HEDGEHOG PATHWAY INHIBITOR; PERITONEAL CARCINOMATOSIS; OVARIAN-CANCER; IN-VIVO; SOLID TUMORS;
D O I：
10.1080/02656736.2017.1312563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Intraperitoneal (IP) drug delivery, either as an intraoperative chemoperfusion or as an adjuvant, repeated instillation, is an established treatment modality in patients with peritoneal carcinomatosis. The efficacy of IP drugs depends on its ability to penetrate the tumour stroma in order to reach their (sub)cellular target. It is known, that drug penetration after IP delivery is limited to a few millimetres. Here, we review the basic tissue transport mechanisms after IP delivery and discuss the biophysical barriers and obstacles that limit penetration distance. In addition, we review the physical and pharmaceutical interventions that have been studied in order to improve delivery of small molecular and macromolecular drugs after IP instillation. These interventions could inform the design of future clinical trials aiming at an improved efficacy of IP-based drug delivery in carcinomatosis patients.
引用
收藏
页码：534 / 542
页数：9
相关论文
共 92 条
[41]   Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma [J].
Kumar, Vidhya ;
Boucher, Yves ;
Liu, Hao ;
Ferreira, Diego ;
Hooker, Jacob ;
Catana, Ciprian ;
Hoover, Andrew J. ;
Ritter, Tobias ;
Jain, Rakesh K. ;
Guimaraes, Alexander R. .
TRANSLATIONAL ONCOLOGY, 2016, 9 (05) :431-437
[42]   Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors [J].
Kyle, Alastair H. ;
Huxham, Lynsey A. ;
Yeoman, Devon M. ;
Minchinton, Andrew I. .
CLINICAL CANCER RESEARCH, 2007, 13 (09) :2804-2810
[43]   PHOTODYNAMIC THERAPY-INDUCED ALTERATIONS IN INTERSTITIAL FLUID PRESSURE, VOLUME AND WATER-CONTENT OF AN AMELANOTIC MELANOMA IN THE HAMSTER [J].
LEUNIG, M ;
GOETZ, AE ;
GAMARRA, F ;
ZETTERER, G ;
MESSMER, K ;
JAIN, RK .
BRITISH JOURNAL OF CANCER, 1994, 69 (01) :101-103
[44]   Tumor microenvironment: The role of the tumor stroma in cancer [J].
Li, Hanchen ;
Fan, Xueli ;
Houghton, JeanMarie .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 101 (04) :805-815
[45]   Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer [J].
Li, Tong ;
Wang, Yak-Nam ;
Khokhlova, Tatiana D. ;
D'Andrea, Samantha ;
Starr, Frank ;
Chen, Hong ;
McCune, Jeannine S. ;
Risler, Linda J. ;
Mashadi-Hossein, Afshin ;
Hwang, Joo Ha .
CANCER RESEARCH, 2015, 75 (18) :3738-3746
[46]  
Lindner P, 1996, CLIN CANCER RES, V2, P311
[47]   PLATINUM DISTRIBUTION IN INTRAPERITONEAL TUMORS AFTER INTRAPERITONEAL CISPLATIN TREATMENT [J].
LOS, G ;
MUTSAERS, PHA ;
LENGLET, WJM ;
BALDEW, GS ;
MCVIE, JG .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (06) :389-394
[48]   OPTIMIZATION OF INTRAPERITONEAL CISPLATIN THERAPY WITH REGIONAL HYPERTHERMIA IN RATS [J].
LOS, G ;
SMINIA, P ;
WONDERGEM, J ;
MUTSAERS, PHA ;
HAVEMEN, J ;
HUININK, DT ;
SMALS, O ;
GONZALEZGONZALEZ, D ;
MCVIE, JG .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (04) :472-477
[49]   Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer [J].
Lu, Ze ;
Tsai, Max ;
Lu, Dan ;
Wang, Jie ;
Wientjes, M. Guillaume ;
Au, Jessie L. -S. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03) :673-682
[50]  
Mahteme H, 2005, ANTICANCER RES, V25, P917
12345678910